|Daily Range||$33.83 - $34.20|
|52-Week Range||$32.29 - $38.71|
|Dividend (Yield)||$0.00 (2.6%)|
|Average Daily Volume||2,468,543|
|Current FY EPS||$1.92|
News & Commentary
Pharmacyclics soars higher following reports that the company may put itself up for sale.
Some companies posted earnings (or outlooks) that missed the market's expectations. Here are three that really caught our attention.
PDLI BioPharma shares slumped today following fourth quarter results.
Achillion Pharmaceuticals Inc., Neuralstem Inc., and Prothena Corp. Plc could all announce news this year that could make shares climb or fall.
Pfizer Inc.'s acquisition of Hospira could signal that investors should embrace biosimilar drugmakers.
Major drugmakers are investing heavily in a disruptive technology that could lead to game-changing breakthroughs in the treatment of cancer. Here's what you need to know.
Exelixis shares popped briefly Thursday. Here's why.
Pfizer has jumped into the promising field of cancer immunotherapy with both feet. Is this effort too little, too late for the pharma giant?
Three Motley Fool experts tell readers what upcoming FDA decisions have caught their eye.
Motley Fool experts offer up insight into three intriguing small-cap biotech stocks.